Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347111 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
- 4
- Study locations
NCT02347111: Recruiting Phase 4 study of Atrial Fibrillation, sponsored by University of Illinois at Chicago.
NCT02347111 is a Phase 4 study of Atrial Fibrillation that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 162 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02347111, a Phase 4 study of Atrial Fibrillation, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
- 4
- Study locations
Study Summary
In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.
Primary Outcome
Subjects will be monitored with the Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) system to assess AF burden. The device will be programmed to optimize the memory for storing AF episode.
Conditions Studied
Interventions
- DRUG Flecainide
- DRUG Sotalol
Study Locations (4)
Illinois
- Jesse Brown VA Medical Center - Chicago
- Rush University Medical Center - Chicago
- University of Illinois at Chicago - Chicago
- Advocate Christ Medical Center - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2020-12-31 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
What NCT02347111 shows while recruiting
NCT02347111 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Flecainide is the first listed.
NCT02347111 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02347111 about?
NCT02347111 is a clinical study titled "Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation". In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger ...
What is the current status of trial NCT02347111?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2020-12-31. Estimated completion is 2026-06-30.
What conditions does trial NCT02347111 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT02347111?
The interventions under investigation include: Flecainide (DRUG), Sotalol (DRUG).
Who is sponsoring clinical trial NCT02347111?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02347111 being conducted?
This trial has 4 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02347111's enrollment target sits among peer trials
162 116th of 202 higher than 87 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
-
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
- NCT05737693 · 162 participants · Phase 2
Enhancing Week-long Psychological Treatment for PTSD With Ketamine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI